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Abstract 
Background 
Cell-derived microparticles are secreted in response to cell damage or dysfunction. 
Endothelial and platelet dysfunction are thought to contribute to the development of multiple 
sclerosis (MS). Our aim here is, first, to compare the presence of microparticles of 
endothelial and platelet origin in plasma from patients with different clinical forms of MS and 
with clinically isolated syndrome. Second, to investigate the effect of microparticles on 
endothelial barrier function. 
Results 
Platelet-poor plasma from 95 patients (12 with clinically isolated syndrome, 51 relapsing-
remitting, 23 secondary progressive, 9 primary progressive) and 49 healthy controls were 
analyzed for the presence of platelet-derived and endothelium-derived microparticles by flow 
cytometry. The plasma concentration of platelet-derived and endothelium-derived 
microparticles increased in all clinical forms of MS and in clinically isolated syndrome 
versus controls. The response of endothelial barriers to purified microparticles was measured 
by electric cell-substrate impedance sensing. Microparticles from relapsing-remitting MS 
patients induced, at equivalent concentrations, a stronger disruption of endothelial barriers 
than those from healthy donors or from patients with clinically isolated syndrome. MS 
microparticles acted synergistically with the inflammatory mediator thrombin to disrupt the 
endothelial barrier function. 
Conclusions 
Plasma microparticles should be considered not only as markers of early stages of MS, but 
also as pathological factors with the potential to increase endothelial permeability and 
leukocyte infiltration. 
Keywords 
Multiple sclerosis, Clinically isolated syndrome, Microparticles, Endothelial barrier function, 
Thrombin 
Background 
Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous 
system (CNS) that predominantly affects young adults. MS is highly heterogeneous and is 
considered by some authors to be a conglomerate of neurological syndromes, in which 
inflammatory damage and demyelination overlap with chronic neurodegeneration. This 
complexity means that current pharmacological treatments are directed towards modifying 
the course of the disease, although there is no effective cure for this pathology [1]. Therefore, 
a better understanding of MS pathogenesis may help to establish new therapeutic strategies. 
In addition, improvement of early diagnostic tools could help speed up the initiation of MS 
treatments. 
The etiology of MS remains unknown but it is most likely a combination of genetic and 
environmental factors deregulating the immune response [2]. Vasculature plays a central role 
in the disease [3-5]. Alteration of endothelial barriers to small molecules and blood cells 
contribute to the leukocyte infiltration that causes inflammation and demyelination [6-9]. 
Endothelial permeability in the brain is altered in different clinical forms of MS even during 
the earlier stages of the disease [3,8]. On the other hand, chronic activation of platelets is also 
associated with MS, although their role or the role of the coagulation cascade in this 
pathology still needs to be clarified [10]. A recent proteomic analysis of active MS lesions 
confirmed the importance of the coagulation cascade, in general, and of thrombin-mediated 
signaling, in particular, in the inflammatory progression of this disease [11]. 
Clinically, MS is classified into relapsing-remitting (RRMS), secondary progressive (SPMS) 
and primary progressive (PPMS) subtypes. In 85% of patients who develop definitive MS, 
onset involves an acute or subacute neurological episode affecting the optic nerves, brainstem 
or the spinal cord, known as clinically isolated syndrome (CIS). Studies of the natural history 
of CIS patients are heterogeneous in terms of the clinical presentation and the duration of the 
follow up, but it is commonly accepted that CIS patients are at high risk of developing MS 
[12]. 
Microparticles (MPs) are small vesicles released by a variety of cell types in response to 
inflammatory mediators [13,14]. These vesicles are able to bind and signal to different cell 
types through the interaction of proteins exposed in their surface with their cell counter-
receptors [13]. MPs have been proposed as markers of a variety of pathological processes 
such as endothelial dysfunction [15,16], systemic lupus erythematosus [17], rheumatoid 
arthritis [17] stroke [18] and thrombosis [19] but their potential role in the progression of 
these diseases is not fully characterized. An increase in circulating MPs of endothelial origin 
has been reported in the relapsing phase of patients diagnosed with the RRMS form, which 
suggests a correlation between MPs and neurological episodes [20]. Platelet-derived MPs 
have also been detected in RRMS patients [21,22], but no comparative analysis of MP levels 
in MS subtypes has been performed to date. 
In the present study we present a comprehensive analysis of circulating platelet- and 
endothelium-derived MPs in the plasma of the different clinical forms of MS. Compared with 
normal control subjects, we found a significant and comparable increase in all subtypes, 
including patients with typical CIS and already recovered, or patients in the remission phase 
of the disease. Interestingly, we found experimental evidence to suggest that plasma MPs 
induce human endothelial barrier dysfunction and thus may play an active role in MS 
progression. RRMS MPs had a stronger effect than CIS or control MPs on transendothelial 
electric resistance (TEER), when analyzed at the same concentration. TEER is inversely 
proportional to endothelial monolayer permeability, indicating that MP composition and 
effect on endothelial barrier differ between MS patients and healthy donors. We also report 
that MS MPs can potentiate the effect on long-term barrier dysfunction of thrombin. Our 
results indicate that MP generation in plasma is an early and permanent consequence of 
inflammatory demyelinating events. 
Results 
We investigated MPs in platelet-poor plasma (PPP) from 49 healthy volunteers and 95 
patients and the possible role of these MPs in endothelial barrier function. The characteristics 
of controls and patients are summarized in Table 1. 
Table 1 Characteristics of controls and patients enrolled in the study 
 Mean age (95% CI) Number (%) of females 
Control (N = 49) 42.70 (23.11-62.95) 26 (53.10) 
Patients (N = 95) 44.35 (11.80-73.88) 62 (66.67) 
         CIS: 12 36.41 (21.69-49.64) 10 (83.33) 
         RRMS: 51 39.95 (11.80-68.51) 35 (68.63) 
         SPMS: 23 53.51 (38.38-73.88) 14 (60.87) 
         PPMS: 9 52.68 (44.06-62.48) 3 (33.33) 
Identification of MPs of platelet and endothelial origin in human plasma 
The PPPs from healthy donors and patients were analyzed by flow cytometry to detect 
circulating vesicles or MPs of less than 3 µm diameter (Figure 1A-C, left panels, Figure 1D-
F, top panels). We found MPs positive for Annexin V, CD42b and CD31 (AnxV + CD42b + 
CD31+), which suggests a platelet origin, and MPs positive for Annexin V and CD31, but 
negative for the CD42b marker (AnxV+/CD42b-/CD31+), which suggest an endothelial 
origin (Figure 1A-B, central and right panels) [20,23]. Prior cytometer adjustments using 
isotype specific controls indicated that the signal from these antibodies was specific (Figure 
1C, right panels, see Methods). Thus, these two types of MPs were defined as platelet-derived 
MPs (PMPs) and endothelial-derived MPs (EMPs). MPs positive for the endothelial marker 
E-Selectin/CD62E + were also found, which confirmed the endothelial origin of an MP 
subset (Figure 1D-F). Prior cytometer adjustments using isotype specific controls indicated 
that the signal from anti E-Selectin/CD62E + antibody was specific (Figure 1E, F, bottom 
panels, see Methods). Hence, EMPs were identified by detecting the markers CD31 and 
CD42 (EMPs-CD31) or CD62E (EMPs-CD62E). 
  
Figure 1 Detection of PMPs and EMPs in plasma. (A-C) Flow cytometry scattergraphs for 
the quantitation of PMPs and EMPs-CD31. MPs smaller than 3 µm were identified by 
cytometry in the presence of 3 µm diameter beads (left graphs, squared area). These MPs 
were positive for Annexin V (central graphs, squared areas). Additional incubation with anti-
CD31 and CD42 antibodies (A, B, right graphs) yielded two populations: AnxV+ MPs 
positive for CD31 and CD42 (Q2), which suggests a platelet origin for this MP subpopulation 
(PMP), and AnxV+ MPs, positive for CD31 and negative for CD42 (Q4), which suggests an 
endothelial origin (EMP). Prior incubation with an antibody isotype control (iso) yielded no 
positive staining (C). (A) Plasma from healthy control, (B, C) plasma from multiple sclerosis 
patient (RR) (D-F) Flow cytometry scattergraphs showing the identification of EMPs-CD62. 
A subset of MPs smaller than 3 µm beads (top graphs, squared area) was positive for an anti-
CD62E antibody (CD62E) (D, E, bottom graphs, squared areas) and negative for an antibody 
isotype control (iso) (F, bottom graph, squared area). (D) Plasma from a healthy control (E, 
F) plasma from multiple sclerosis patient (RR). 
Plasma levels of PMPs and EMPs are elevated in patients with CIS and all the 
clinical forms of MS 
Plasma EMPs may reflect age-related endothelial dysfunction [24]. In the healthy donors 
included in our study, ranging from 24 to 62 years of age, no statistically significant 
differences in MP number could be attributed to gender or age (Figure 2A-F). This suggests 
that any change detected in CIS and MS patients cannot be attributed to these parameters. 
Next, we performed a comparative analysis of circulating MP levels between these control 
individuals and patients with CIS and all clinical forms of MS. First, the analysis of the pool 
of all MS patient samples revealed that the mean ± SD of the counts/µl plasma were 
significantly higher than in healthy controls for the three types of MPs analyzed: 27,203 ± 
16,767 for PMPs vs. 15,646 ± 11,901 for controls (p < 0.001) (Figure 1A, B; Figure 3A) 
6,527 ± 4,554 EMPs-CD31 vs. 2,202 ± 2,783 for controls (p < 0.001) (Figure 1A, B; Figure 
3B), and 746 ± 642 for EMPs-CD62E vs. 418 ± 289 for controls (p < 0.05) (Figure 1D, E; 
Figure 3C). An elevated MP content was also detected when each clinical form of MS was 
individually analyzed, including the progressive forms, SPMS and PPMS, which are 
considered to have a less important inflammatory component (Figure 4). The MP counts 
(mean ± SD) for each form of MS is summarized in Table 2. PMPs were higher than controls 
in CIS and all the MS forms, but the increase was not statistically significant for CIS patients 
(Figure 4A, Table 2). In addition, remarkable and statistically significantly higher levels of 
EMPs-CD31 were observed in samples from CIS and all MS forms compared to control 
donors (Figure 4B, Table 2). Finally, compared to control subjects, EMPs-CD62 were 
augmented in CIS and all the MS forms, although this increase was statistically significant 
only for CIS patients: 646 ± 195 vs. 418 ± 289 (p < 0.05) (Figure 4C). In summary and 
regarding the absolute values of MP counts, our results show that patients with CIS and all 
the clinical forms of MS have comparable levels of circulating MPs in plasma, which are 
higher than those in healthy individuals (Table 2). 
Figure 2 Gender and age have no effect on PMP and EMP counts in healthy controls. 
(A-C) Comparison of PMPs (A), EMPs-CD31 (B) and EMPs-CD62E (C) counts between 
female and male healthy controls. MPs were identified and quantified by cytometry as in 
Figure 1. No significant differences were observed (Student’s t-test). (D-F) No significant 
changes in PMPs (D), EMPs-CD31 (E) and EMPs-CD62E (F) levels were detected in 
relation to age in healthy donors. 
Figure 3 Circulating MPs are more abundant in MS patients. Comparison of PMPs (A), 
EMPs-CD31 (B) and EMPs-CD62E (C) counts in healthy controls (Ct) and MS patients. MPs 
were identified and quantified by cytometry as in Figure 1. (***p < 0.001, *p < 0.05 vs. 
healthy controls). 
Figure 4 MPs in the different clinical forms of MS. Comparison of PMP (A), EMPs-CD31 
(B) and EMPs-CD62E (C) counts in healthy controls (Ct) and patients with CIS or MS. (*p < 
0.05, **p < 0.01, ***p < 0.001 vs. healthy controls). CIS, clinically isolated syndrome. 
RRMS, relapsing, remitting MS. SPMS, secondary progressive MS. PPMS, primary 
progressive MS. Differences between pairs were assessed by Student’s t-test. MPs 
concentrations were not able to discriminate between the different clinical forms of MS 
(ANOVA). Numerical data and results of statistical analysis are shown in Table 2. 
Table 2 Circulating MP counts in healthy controls and the different clinical forms of MS 
 
PMPs mean (SD) counts/µl EMPs-CD31 mean (SD) counts/µl EMPs-CD62 mean (SD) counts/µl PMPs p vs. Ct EMPsCD31 p vs. Ct EMPsCD62 p vs. Ct 
Control 15,646 (11,901) 2,202 (2,784) 418 (289)    
CIS 30,936 (22,550) 7,964 (6,888) 646 (195) n.s. <0.05 <0.05 
RRMS 28,929 (18,247) 7,136 (6,088) 511 (231) <0.001 <0.001 n.s. 
SPMS 34,188 (29,511) 7,512 (5,962) 629 (644) <0.01 <0.001 n.s. 
PPMMS 26,422 (9,865) 6,460 (3,610) 699 (621) <0.05 <0.001 n.s. 
(n.s.: not statistically significant). p values compared to Control group, Student’s t-test. 
MPs induce endothelial barrier dysfunction 
Endothelial barrier dysfunction is a hallmark of MS. To gain insight into the role of 
circulating MPs in MS we compared the effect on endothelial barrier function of MPs 
isolated from patients and healthy controls. We used an electric cell-substrate impedance 
sensing (ECIS) system that measures in real time the resistance of endothelial monolayers to 
a weak electric current that cause no effects on cells. This is called transendothelial electric 
resistance (TEER) and is inversely proportional to the permeability of the monolayer. To 
address the relevance of MP-mediated TEER changes in each endothelial cell type, cells were 
incubated in parallel with the inflammatory cytokine tumor necrosis factor (TNF) as a 
positive control of in vitro barrier disruption (Figure 5A) [25,26]. First, monolayers of human 
umbilical vein endothelial cells (HUVECs) were incubated with growing concentrations of 
MPs from healthy donors, CIS patients and RRMS (RR-MPs) patients, the latter taken as 
paradigm of patients in which the disease has already progressed (Figure 5B and C). Control, 
CIS and RR-MPs had no significant effects on constitutive TEER at concentrations of 250 
and 500 MP/µl. In contrast, MPs from RRMS patients notably disrupted the endothelial 
barrier after 4 h of incubation at 1000 MP/µl (Figure 5B-D; Additional file 1: Figure S1A). 
These MPs decreased normalized TEER by 77.14 ± 21.94%, (p = 0.004) (Figure 5D). Such 
decrease was expressed as the percentage of the difference between the TEER values 
obtained from unstimulated HUVEC monolayers (before incubation with MPs) and the 
TEER values measured in absence of cells (see Methods). In addition, this decrease was 
comparable or even stronger than that caused by TNF exposure (Figure 5A and 5D, 
discontinuous line). In contrast, barrier alterations that control and CIS MPs induced on 
endothelial barrier function at 1000 MP/ml were clearly below the effect of TNF and were 
considered minor (Figure 5A-D). Consistent with the loss of TEER upon exposure to MPs 
from RRMS patients, the confocal analysis of endothelial cells incubated with these MPs 
showed the appearance of intercellular gaps, detected by staining of F-actin and the junctional 
markers VE-cadherin and ZO-1 (Figure 5E, mask, see Methods). In contrast, intercellular 
gaps were absent or rare in cells incubated with control and CIS MPs. These intercellular 
gaps were measured as the percentage of empty spaces found in different regions of the cell 
monolayer and increased from 0.20 ± 0.23% in cells exposed to control MPs to 1.38 ± 0.59% 
in cells exposed to RR-MPs (p < 0.02) (Figure 5E). Together, these data suggest that MPs 
from RRMS patients have composition and signaling properties different to control and CIS 
MPs. To confirm this, we tested the effect of RR-MPs in a cell model of human endothelium 
from the blood–brain barrier (BBB), the HCMEC/D3 cells [27]. We found no effect of MPs 
on HCMEC/D3 monolayers at concentrations of 400 (Figure 6A) and 1000 MP/µl (not 
shown). However, barrier disruption caused by RR-MPs at 2000 MP/µl was stronger than that 
produced by TNF or by control MPs at the same concentration (Figure 6A, Additional file 1: 
Figure S1B). In the presence of RR-MPs, resistance decreased by 16.83 ± 12.19% (p < 0.04), 
whereas in the presence of 2000 MP/µl of control MPs, the resistance decreased only by 9.00 
+ 11.7% (p = 0.39), which was no statistically significant. 66% of RR-MPs had an effect 
higher than TNF versus only 20% for control MPs (Figure 6A). In contrast with the effect 
observed in HUVECs, the incubation with RR-MPs did not induce big intercellular gaps in 
HCMEC/D3 cells, but caused a significant decrease of the immunofluorescence staining of 
VE-cadherin and ZO-1 at cell-cell junctions (Figure 6B). This was expressed as the junctional 
index, in which the ratio between the staining intensity at cell borders and the staining at the 
cell inner area was measured per cell in confluent cell monolayers. This ratio was normalized 
to 1 for HCMEC/D3 that had not been exposed to MPs (see Methods). Junctional index 
significantly decreased only in the presence of RR-MPs. It was reduced to 0.14 ± 0.06 (p < 
0.03) for VE-cadherin staining and to 0.33 + 0.03 (p < 0.002) for ZO-1 staining. Thus, 
healthy donors not only have significantly less MPs in plasma than MS-patients. At equal 
concentrations, MPs from RRMS patients provoke higher disruption of endothelial barrier 
properties that those from healthy donors. 
Figure 5 Effect of MPs on HUVEC barrier function. (A) TNF is a paradigmatic stimulus 
that induces significant and progressive reduction of TEER (normalized TEER) (B, C) 
Normalized TEER of confluent HUVECs left untreated (Medium) or exposed to MPs at the 
indicated concentrations. MPs from one healthy control (Control 3) and one RRMS patient 
(RR 3) were compared in a (B) and MPs from one CIS patient and from a RRMS patient (RR 
2) were compared in (C). (D) Percentage of TEER decrease induced after 14 hours of 
incubation with Control, CIS and RR-MPs at 250, 500 and 1000 MP/µl (see Methods). 
Average TEER decrease in response to TNF is marked by discontinuous lines. **p = 0.004. 
(E) HUVECs left untreated (Medium) of previously treated for 14 h with MPs from a healthy 
control and a RRMS (RR) patient at 1000 MP/µl were stained for the cell-cell junction 
markers VE-cadherin and ZO-1 and for filamentous actin (F-actin). Semi-automated image 
processing identified intercellular gaps in the images (mask) that were quantified respect to 
the total area of the cell monolayer (right graph). *p = 0.01. Bar, 20 µm. 
Figure 6 Effect of MPs on hCMEC/D3 barrier function. (A) Percentage of TEER decrease 
after 14 hours of incubation with the indicated MPs at 400 and 2000 MP/µl. Left graph, 
control donors. Right graph, RRMS patients (RR). Average TEER decrease in response to 
TNF is marked by discontinuous lines. Bottom table shows the percentage of MPs inducing a 
response stronger than control TNF on the endothelial barrier. *p = 0.04. (B) VE-cadherin, 
ZO-1 and F-actin staining in HCMEC/D3 cells exposed for 14 h to MPs from a donor and a 
RRMS patient. MPs did not induced big gaps in HCMEC/D3, as in HUVECs, but, instead, 
RR-MPs dispersed the junctional staining of VE-cadherin (top right graph) and ZO-1 (bottom 
right graph) quantified as the ratio between the staining intensity at cell-cell borders and at 
the inner cell area (Junctional index). **p < 0.03, ***p < 0.002. Bar, 20 µm. 
The importance of thrombin in the inflammatory progression of experimental MS has 
recently been shown [11]. Thrombin is an inflammatory mediator that induces acute barrier 
contraction and subsequent long-term inflammatory activation of the endothelium [28], so we 
hypothesized that MPs with no apparent effect on endothelial barriers on their own, may 
sensitize cells to thrombin-mediated barrier disruption. Twenty-two hours after the addition 
of MPs, the endothelial responses to thrombin were analyzed in HUVECs and HCMEC/D3 
monolayers in which TEER had not been previously altered by the initial incubation with 
MPs. Whereas HUVEC monolayers were transiently but completely disrupted by thrombin 
(Figure 7), we unexpectedly found that the HCMEC/D3 cell line barely contracted in 
response to this inflammatory mediator (not shown). This suggests that transformed 
HCMEC/D3 cells may lack some protein machinery important for a full response to 
thrombin. We thus studied the effect of MPs and thrombin only in HUVEC barriers. The 
acute phase of contraction upon thrombin stimulation and the subsequent TEER recovery 
were not affected by the presence of MPs in these endothelial cells (Figure 7). However, 
between 3 and 8 h after thrombin stimulation, cells initially exposed to RR-MPs at 500 MP/µl 
gradually reduced their barrier integrity. In contrast, the TEER decrease between 3 and 8 h 
after thrombin activation was transient and minor in cells previously exposed to control or 
CIS MPs (Figure 7). Together these data suggest that MPs have an effect on endothelial 
barrier function either on their own, at higher concentrations, or when acting synergistically 
at lower concentrations with a proinflammatory stimulus, namely thrombin, important for MS 
progression. Together, these data suggest that chronic exposure to MPs may contribute to a 
long-term increase in extravasation of molecules and cells from the bloodstream in MS 
patients. Further investigation into the protein composition of MPs from different clinical 
subtypes may help the design of therapies in which the endothelial permeability increase 
associated with this inflammatory disease could be prevented. 
Figure 7 Synergistic effect of MS-MPs and thrombin on endothelial barrier function. 
Top graph. Representative experiment in which HUVECs were incubated with MPs at 
concentrations between 250 and 1000 MP/µl for 22 h. Then, 1 U/ml of thrombin was added 
to those monolayers showing no alteration of TEER in response to MPs. After thrombin-
induced acute contraction and subsequent barrier recovery, HUVECs preincubated with 
RRMS MPs (RR3) undergo long-term decrease in TEER. Bottom table. Percentage of 
Control (3 samples), CIS (2 samples), and RR-MPs (3 samples) in which 500 MP/µl had no 
apparent effect on barrier function, but induced long-term TEER decrease after thrombin 
stimulation. 
Discussion 
In this study we show that the different clinical forms of MS, including the progressive 
forms, are associated with platelet and endothelial dysfunction, as determined by an increase 
in the number of circulating platelet- and endothelial cell-derived MPs [21,29]. Moreover, we 
demonstrate that these vesicles may play an active role in the progression of the disease by 
increasing endothelial monolayer permeability. 
Circulating microparticles as potential markers of CIS and MS 
Different soluble markers have been described for MS in plasma or cerebrospinal fluid [30-
32]. Among others, platelet endothelial cell adhesion molecule (PECAM)-1 (CD31) and E-
Selectin (CD62E) are present in microvesicles derived from endothelial cells during 
apoptosis or upon inflammatory stimulation [29] and their concentration in plasma may 
account for the status of the endothelium [33]. In our study we observed a remarkable 
increase in PMPs and both EMPs in all MS clinical forms. The fact that elevated levels of 
EMPs in CIS patients were also found indicates that these circulating vesicles are a chronic 
and early feature in patients experiencing proinflammatory demyelinating pathologies. Our 
results extend and are partly consistent with a previous report showing an increase in EMPs, 
defined as CD51+ in both the exacerbation and remission phases of RRMS patients. 
Interestingly, these authors find no differences in CD31+/CD42b- MPs in patients during the 
remission phase, although they elegantly show that isolated endothelia from patients in both 
the exacerbation and remission phases of the disease release similar levels of both CD31+ 
and CD51+ MPs to plasma, which are higher than those released by the endothelium of 
healthy controls [20]. Collectively and in line with our results, this work indicates that in the 
remission phase of RRMS, high levels of EMPs can be found. However, MPs from the 
exacerbation and remission phases of the disease probably differ in composition. On the other 
hand, we have found that plasma PMPs were significantly increased in each MS subtype, 
consistent with the elevated circulating PMPs previously found in RRMS. These data are also 
consistent with a pivotal role for platelets in MS [21,34]. PMPs were also elevated in CIS 
patients, but this increase was not statistically significant. This suggests that platelet 
dysfunction may occurs later than to endothelial dysfunction and when the disease is 
definitively progressing. Indeed, platelets have been found in human MS lesions and in the 
CNS of mice in the EAE model. Platelet depletion in the EAE model ameliorated the disease, 
which was associated with a reduction in recruitment of leukocytes to the CNS. Similar 
results were observed after treatment with an anti-CD42b antibody. It is interesting to note 
that CD42b is present at the PMP surface and therefore the potential role of these vesicles in 
the progression of the disease needs to be considered. 
Signals that impair BBB function in MS are initially originated in the central nervous system. 
It is of note that in the early stages of this pathology, the microglia releases reactive oxygen 
species, TNF and IFN-γ, all of which can induce MP release [35]. Therefore, the initial 
inflammatory foci initiating the progression of the disease may cause the early secretion of 
EMP. In summary, we have observed an increase in circulating EMPs both in CIS and the 
remitting phase of RRMS, suggesting enduring endothelial dysfunction from the very early 
stages of demyelinating pathologies. These results make PMPs and EMPs good candidates 
for clinical markers to identify and discriminate between CIS and early MS. 
Circulating microparticles as active players in MS progression 
The remarkable ability of MPs to induce cell signaling and to promote endothelial 
dysfunction has already been reported [36]. PMPs may activate leukocytes and induce their 
trasendothelial migration [37]. Moreover, MPs promote a procoagulant status due to the 
presence of phosphatidylserine in the outer part of the membrane [38]. All this evidence 
suggests a potential role for MPs in the progression of different pathologies, including MS. 
The endothelial beds are highly exposed to circulating MPs and therefore, more likely to 
respond to MP-mediated signaling. The data presented here demonstrate that MPs alone 
increase endothelial permeability. Moreover, this effect differs between definitive MS, 
stronger, and CIS patient and control donors, which are more attenuated when compared at 
the same concentration, suggesting differences in the composition of these microvesicles. 
Various mechanisms could mediate the effect of MPs on endothelial barrier function. MPs 
expose surface receptors with the potential to regulate endothelial permeability. The marker 
CD31, used for the identification of EMPs, can establish homotypic interactions and 
modulate endothelial permeability [26]. EMPs also regulate the production of reactive 
oxygen species (ROS) [39]. ROS increase causes disruption of the endothelial barriers. On 
the other hand, MPs from microvascular endothelial cells and from atherosclerotic plaques 
contain matrix metalloproteinases involved in the cleavage and shedding of surface proteins, 
including that of TNF [40,41]. Thus, MPs may contribute to the release of cytokines that 
locally increase permeability. Indeed, MPs have been shown to act as proinflammatory 
agents. MPs from monocytes contain inflammatory cytokines with the potential to modulate 
permeability and components of the inflammasome. These MPs activate the transcription 
factor NF-κB and induce the expression of adhesion receptors in the endothelium [42]. 
Finally, MPs also transport RNA and micro (mi) RNA, which have the potential to modulate 
protein expression in the target cell [43]. Some miRNAs, such as miRNA155 negatively 
affects BBB function during neuroinflammation [44]. Hence, the analysis of the different 
composition of healthy and MS microparticles could reveal novel targets for preventing 
endothelial barrier disruption during the progression of the disease. 
MS is considered to be a chronic inflammatory disease in which several inflammatory 
mediators play a relevant long-term function in its progression. Permanent exposure to these 
mediators is probably the origin of the MP increase but, importantly, it may also amplify the 
effect of MPs on the endothelium. In the EAE model, it has been reported that thrombin 
inhibition ameliorates the neurological symptoms, indicating a deleterious effect of this 
mediator in the exacerbation phase [11]. In MS, various proteins involved in coagulation, 
including tissue factor, which activates thrombin, become more abundant in chronic active 
plaques [11]. Thrombin is therefore a cytokine at the crossroads of inflammation and 
coagulation with a remarkable ability to signal to and to alter the barrier properties of 
endothelial cells, thereby possibly contributing to the progress of MS. Our data indicate that 
preincubation with RR-MPs has a long-term effect on the endothelial barrier response to 
thrombin-mediated challenge, which induces a secondary decrease in TEER between 3 and 8 
h post-stimulation. As mentioned above, MPs can deliver proinflammatory molecules. This 
synergic effect on thrombin-mediated signaling occurs within a time frame compatible with 
the modulation of the expression of genes related to inflammation and barrier function [28] 
rather than an effect on acute actomyosin-mediated contraction [45]. Therefore, MS-MPs 
may alter the vasculature on their own, or potentiate the effects of proinflammatory mediators 
on endothelial barrier dysfunction. This may have important and unexplored consequences 
for the progression of MS. Further studies are necessary to determine which components of 
MS-MPs are responsible for the observed effects. 
Conclusions 
Our findings demonstrate that platelet and endothelial functions are altered in the different 
clinical forms of MS, since patients show an increase in circulating MPs of endothelial and 
platelet origin. In addition, endothelial MPs are also significantly increased in CIS patients. In 
vitro, MPs from MS patients disrupt endothelial barriers and may thus cooperate in the 
progression of the disease. 
Methods 
Patients and controls 
Eighty-three adult MS patients who met the criteria of Poser [22] and MacDonald [46], 12 
adult patients with a typical CIS, suggestive of MS, and 49 healthy adult volunteers gave 
their written informed consent and were enrolled in the study, which was approved by the 
Ethics Committee of the Hospital Universitario Central de Asturias (Oviedo). MS 
exacerbation was defined as a worsening of neurological impairment or the appearance of a 
new symptom attributable to MS and lasting for at least 24 hours. Patients were exacerbation-
free and none had any corticosteroids for at least one month before entering the study. 
Sample collection 
Venous blood was collected in citrate vacutainer tubes with a 21G needle. Blood was 
centrifuged within 20 min of extraction. PPP was obtained by centrifugation for 20 min at 
1550 g. Aliquots were immediately frozen and preserved at −80°C until use. 
Antibodies and chemicals 
PE-conjugated anti-CD31 was from eBioscience (San Diego, CA, USA). APC-conjugated 
anti-CD42b was purchased from BD Bioscience (Erembodegem, Belgium). FITC-conjugated 
anti-CD62E (E-Selectin) was obtained from Santa Cruz Biotech (Santa Cruz, CA, USA). 
FITC-conjugated Annexin V was from ImmunoStep (Salamanca, Spain). Recombinant 
fibronectin, thrombin and other chemicals were provided by Sigma-Aldrich (St Louis, MO, 
USA). 
Flow cytometry 
A volume of 20 µl of PPP was incubated with 2 µl of the indicated antibodies or their 
corresponding isotypic controls at room temperature for 20 min with gentle shaking (100 
rpm). Following this, 900 µl of PBS containing a fixed number of 3-µm latex beads were 
added. For the AnxV + MP determination, 4 µl of FITC-conjugated AnxV were added with 
the antibodies and the sample was subsequently diluted in 900 µl of AnxV buffer containing 
the latex beads. MPs present in the samples were measured in a FACSAria cytometer with 
the FACSDiva software (BD Bioscience, Erembodegem, Belgium). To determine the 
fluorescence background, isotypic antibodies for each fluorochrome were used. 
Compensation adjustments were made based on fluorescence minus one (FMO) controls, 
which consist of all the reagents but the one of interest. The absolute number of MPs was 
estimated through the formula: [MP/µl plasma] = (n° events counted per test * n° beads per 
test) / (n° events in bead region * test volume). 10,000 beads were routinely collected. All 
solvents were 0.22-µm filtered. 
Cell culture 
HUVECs were purchased from Lonza (Barcelona, Spain) and grown in fibronectin-coated 
plates in EBM-2 medium supplemented with 2% fetal bovine serum, glutamine, 
penicillin/streptomycin and the endothelial cell growth supplement EGM-2 [26]. 
Immortalized hCMEC/D3 cells were obtained as previously described [27] and grown in rat 
collagen-I-coated plates (Cultrex) in EBM-2 medium supplemented with 5% fetal bovine 
serum, penicillin/streptomycin, hydrocortisone (Sigma), ascorbic acid (Sigma), Chemically 
Defined Lipid Concentrate (Invitrogen), HEPES (PAA The Cell Culture Company) and 
human bFGF (Sigma). 
Isolation of MPs 
PPP from patients and controls was centrifuged at 3200 g for 30 min and subsequently at 
13,000 g for 10 min to remove cell debris. Supernatants were then centrifuged at 18,000 g for 
45 min and the pellet of MPs washed and resuspended in EC culture medium. Final MP 
counts were determined by flow cytometry. 
Endothelial permeability assays 
Cells were grown to confluency on fibronectin-coated (HUVECs) or rat-collagen-I coated 
(hCMEC/D3) eight-well array culture-ware (8WE10, Ibidi, München, Germany) specific for 
transendothelial electric resistance (TEER) measurements with the electric cell substrate 
impedance sensing (ECIS) system 1600R (Applied Biophysics [26]. The experiments were 
performed in wells in which the electric resistance of the EC monolayer, which is inversely 
proportional to its permeability, had reached a steady-state. EC monolayers were incubated 
with MPs isolated from controls and patients and the effect on permeability monitored by at 
least 14 h. The percentage of maximum permeability increase induced by MPs was calculated 
taking into account that the average normalized resistance (NR) for an ECIS electrode 
containing no cells or fully contracted cells (maximum permeability) is 0.35, whereas 
untreated, control confluent monolayers yielded an average NR value of approximately 1.10 
for hCMEC/D3 and 0.95-1.00 for HUVECs 14 h after the beginning of the experiment. Thus, 
the percentage of reduction in resistance was calculated applying the formula [(NR 
unstimulated cells-NR MPs)/0.75] X100, NR being the normalized resistance value 14 h after 
the beginning of the ECIS reading. A parallel incubation with 10 ng/ml human TNF (R & D) 
was performed to measure the responsiveness of hCMEC/D3 and HUVEC barriers to 
inflammatory challenges. 22 h after exposure to the indicated MPs, the ECIS was paused, 
1U/ml of human thrombin was added and its effect recorded in the instrument for an 
additional period of 10 h. 
Immunofluorescence analysis 
Endothelial cells were grown at confluency for 48 h in Ibidi µ-slide 8 well dishes pre-coated 
with fibronectin (HUVECs) or rat-collagen-I (hCMEC/D3). Cells were incubated with MPs 
from control donors or patients at the indicated concentrations for at least 14 h. In parallel, 
ECIS assays were performed with the same MPs to detect changes in endothelial barrier 
function. Then, cells were fixed in 4% paraformaldehyde for 20 min, rinsed and treated with 
10 mM glycine for 5 min to quench the aldehyde groups. The cells were then permeabilized 
with 0.2% Triton X-100, rinsed and incubated with 3% bovine serum albumin in PBS for 15 
min. Cells were incubated for 30 min with the indicated antibodies at 37°C, rinsed in PBS 
and incubated for 30 min with the appropriate fluorescent secondary antibodies. Actin 
filaments were detected with fluorescent phalloidin. Confocal laser scanning microscopy was 
carried out using a Zeiss LSM 510 microscope equipped with a 63× 1.3 NA oil immersion 
objective. 
Intercellular gaps in confluent monolayers were quantified using Image J. Ten images 
containing around twenty cells were quantified per condition and experiment in three 
different experiments. The image contrast was semi-automatically increased to saturation, so 
regions in the confluent monolayer that yielded no signal in all the fluorescence channels 
were taken as empty areas or intercellular gaps, and selected by creating a threshold. The 
percentage of empty areas respect to total image area was calculated. To show the empty 
areas, the region obtained with the threshold was blue-colored and flattened to the original 
image. 
When intercellular gaps were not big enough to be detected, the junctional index was 
calculated. The junctional index quantified the junctional/non-junctional staining ratio for 
junctional proteins and was also calculated using ImageJ. Ten images containing around 
twenty cells were quantified per condition and experiment. The background was substracted 
using the BG Substraction from ROI pluging from Image J. A region that selected the total 
area of a single cell in the confluent monolayer was created. This initial region was made 5 to 
10 pixels smaller using enlarge tool. The intensity of this smaller region was quantified as 
non-junctional intensity of VE-cadherin or ZO-1. The area between the initial region and the 
smaller region was considered as junctional. The junctional index was normalized taking as 1 
the ratio from cells not exposed to MPs. 
Statistical analysis 
Statistical analyses were performed using SPSS 15.0 for Windows. One-way ANOVA 
(analysis of variance) was used to analyze differences among three or more groups. Pairs of 
groups were compared using Student’s t test (parametric data) or the Mann Whitney U test 
(nonparametric data). Bivariate correlations were estimated by Spearman’s rank correlation 
(R). All tests for statistical significance were two-tailed and values of p < 0.05 were 
considered statistically significant. 
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